Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone
Multiple cellular pathways can lead to acquired resistance to ALK inhibitors. A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R
Researchers have discovered that inhibition of RIP1 kinase blocks the progression of multiple sclerosis in an immune-induced demyelination mouse model (EAE) but not a chemically-induced one
Website Created by Advanta Advertising LLC.
